Cells of the osteoblast lineage are increasingly identified as participants in whole-body metabolism by primarily targeting pancreatic insulin secretion or consuming energy. Osteocytes, the most abundant bone cells, secrete a Wnt-signaling inhibitor called sclerostin. Here we examined three mouse models expressing high sclerostin levels, achieved through constitutive or inducible loss of the stimulatory subunit of G-proteins (Gsa in mature osteoblasts and/or osteocytes). These mice showed progressive loss of white adipose tissue (WAT) with tendency toward increased energy expenditure but no changes in glucose or insulin metabolism. Interestingly beige adipocytes were increased extensively in both gonadal and inguinal WAT and had reduced canonical b-catenin signaling. To determine if sclerostin directly contributes to the increased beige adipogenesis, we engineered an osteocytic cell line lacking Gsa which has high sclerostin secretion. Conditioned media from these cells significantly increased expression of UCP1 in primary adipocytes, and this effect was partially reduced after depletion of sclerostin from the conditioned media. Similarly, treatment of Gsa-deficient animals with sclerostin-neutralizing antibody partially reduced the increased UCP1 expression in WAT. Moreover, direct treatment of sclerostin to wild-type mice significantly increased UCP1 expression in WAT. These results show that osteocytes and/or osteoblasts secrete factors regulating beige adipogenesis, at least in part, through the Wnt-signaling inhibitor sclerostin. Further studies are needed to assess metabolic effects of sclerostin on adipocytes and other metabolic tissues.
Introduction

M
ice with genetic manipulation of osteoblast lineage cells or their intracellular signaling show altered body metabolism and composition. (1) (2) (3) (4) (5) (6) (7) (8) (9) These studies indicate the presence of at least two mechanisms through which osteolineage cells participate in global energy metabolism. In the first mechanisms, the osteoblast-specific factor undercarboxylated osteocalcin (ucOCN) has been shown to be a potent regulator of insulin secretion and insulin sensitivity. (1, 3, 5) However, decreased ucOCN does not explain reduced body fat in mice with inducedosteoblast deficiency, (8) indicating the presence of other ucOCN-independent mechanism(s) through which osteolineage cells regulate body fat accumulation. Inducible osteocyte deficiency in adult mice also results in profound loss of white adipose depots, which can be normalized by restoring osteocytes. (9) Interestingly, the decrease in body adiposity is present despite normal serum insulin, glucose, and osteocalcin levels. (9) Recently, Frey and colleagues (10) identified LRP5-Wnt signaling in osteoblast as capable of regulating body adiposity independent of changes in glucose metabolism or ucOCN levels.
Mice lacking LRP5 in osteoblasts have increased body adiposity due to reduced LRP5-mediated energy consumption by osteoblasts. (10) Here we report that G-protein coupled receptor(s) (GPCR), signaling through Gsa, functions as another class of signaling in osteolineage cells capable of influencing body adiposity. We identify the secreted Wnt inhibitor sclerostin as the molecule capable of inducing beige adipogenesis and we identified osteocytes as important regulators of fat metabolism.
Beige adipocytes are brown-adipocyte-like uncoupling-protein 1 (UCP1)-positive cells in white adipose tissue (WAT) that respond to cold-exposure and sympathetic control in a manner similar to brown adipose tissue (BAT). (11, 12) Wnt signaling is a multiphasic regulator of white and brown adipogenesis. Wnt ligands bind to Frizzled and LRP5/6 co-receptors to translocate b-catenin to the nucleus and activate gene expression. Activation of Wnt-b-catenin signaling in early adipocytes inhibits both white and brown adipocyte differentiation and vice versa. (13) (14) (15) (16) However, in differentiated brown adipocytes, Wnt signaling suppresses expression of UCP1 through repression of PGC1a. (17) This raises a possibility that Wnt signaling may also play a role in beige adipogenesis. Two previous studies support this notion. Although inactivating mutation in LRP6 in patients is associated with metabolic syndrome and diabetes, (18) closer examination of LRP6 þ/-mice show significantly increased UCP1 expression in both brown and beige depots. (19) LGR4 is a receptor for R-spondins that enhances canonical Wnt signaling in cooperation with Frizzled. (20) Global LGR4-deficient mice have increased brown and beige adipogenesis and UCP1 activity. (21) Sclerostin is secreted specifically by osteocytes (22, 23) and it antagonizes Wnt signaling by binding to LRP5, LRP6, or both. (24) Sclerostin is a negative regulator of bone formation (25) and a sclerostin-neutralizing antibody is a promising treatment for osteoporosis. (26) Paradoxically, high circulating sclerostin is positively associated with higher bone density, (27, 28) suggesting that the effects of sclerostin are more complex. Serum sclerostin is also positively correlated with higher gonadal fat and vertebral bone marrow fat in humans. (28, 29) Recently, continuous sclerostin treatment has been shown to increase differentiation of white adipogenic cell line 3T3-L1. (30) However, the role of sclerostin on beige adipogenesis remains unknown.
We have shown that Gsa is a strong negative regulator of sclerostin secretion by osteocytes (31) and mice lacking Gsa in osteocytes have increased sclerostin expression. (32) Here, we examined three mouse models of Gsa deletion in osteoblasts and/or osteocytes that show dramatic increase in beige adipogenesis and decreased body fat. These changes were not associated with changes in glucose/insulin metabolism or ucOCN levels. Here we show that the increased beige adipogenesis is, at least in part, via increased sclerostin secretion.
Materials and Methods
Mice
All animal experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Massachusetts General Hospital and Boston University. DMP1-Cre , and DMP1-ERT2-GsaKO mice were generated by mating Gsa flox/flox mice (33) (kindly provided by Lee Weinstein) with 10 kb DMP1-Cre (34) (kindly provided by Jerry Feng), OC-Cre, (35) and DMP1-ETR2-Cre mice, (36) respectively. Littermates lacking Cre expression were used as controls for all experiments. The genotyping primers and tissuespecific DNA recombination details are described in the Supporting Methods. For postnatal Gsa deletion, DMP1-ERT2-GsaKO mice were injected with 100 mL of tamoxifen solution from ages 10 to 18 weeks. For sclerostin neutralization, 16-week-old mice were injected subcutaneously with antisclerostin antibody (100 mg/kg, two times per week; kindly provided by Michaela Kneissel, Novartis) for 2 weeks. For treatment of wild-type mice, 8-week-old to 10-week-old wild-type mice were injected intraperitoneally with 100 mg/kg body weight of mouse recombinant sclerostin (R&D Systems, Minneapolis, MN, USA) every day for 3 weeks.
Body composition and metabolic status analysis
Noninvasive body composition was measured in anesthetized mice by DXA (Lunar PIXImus II GE Healthcare) to obtain absolute body fat and lean mass. Absolute measurements were normalized to total body weights to account for decreased body weights in the GsaKO mice. Absolute weights of individual organs (gonadal, inguinal, and brown adipose depots, and pancreas) were measured during necropsy and normalized to total body weights. Food intake, energy expenditure, and physical activity were measured in metabolic cages followed by hyperinsulinemiceuglycemic clamp measurements at the National Mouse Metabolic Phenotyping Center at the University of Massachusetts.
Serum measurements
Blood glucose levels were measured using Precision Xceed Pro monitor (Abbott, Lake Bluff, IL, USA 
In vitro cultures
Osteocytic cell line Ocy454 was generated from mouse long bones as described (31) and a single-cell subclone of Ocy454 cells was used. (37) Gsa knockdown using shRNA or knockout using "clustered regularly interspaced short palindromic repeats" (CRISPR)/Cas9 was performed as described in the Supporting Methods. Primary beige adipocyte differentiation and sclerostin depletion from conditioned media was done as described in the Supporting Methods.
Quantitative PCR
Total RNA was extracted from tissues or cells using Trizol reagent (MRC). First-strand cDNA was generated using the High Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA, USA), and qPCR was performed using SYBR Green Master Mix in a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Target genes were normalized to one housekeeping gene for in vitro samples or to at least three housekeeping genes using geometric averaging methods. (38) Primers used are listed in the Supporting Methods.
Results
Mice lacking Gsa in osteocytes have severely decreased WAT mass
As reported, (39, 40) the Cre-loxP recombination in DMP1-GsaKO mice were observed in skeletal tissues as well as skeletal muscle (Fig. 1A) . Gsa mRNA expressions were significantly reduced in osteocyte-enriched bones and skeletal muscle (Fig. 1B) . Gsa protein expressions were decreased in skeletal tissue but not in skeletal muscle (Fig. 1C) . Cre-loxP recombinations were absent Gsa mRNA expression in osteocyte-enriched bones (OEBE), gastrocnemius muscle, GWAT, and InWAT from 21-week-old control and DMP1-GsaKO mice (n ¼ 5). (C)Gsa and GAPDH protein levels in osteocyte-enriched femurs and other metabolic tissues (n ¼ 3). The bands were quantified as Gsa-to-GAPDH ratio. (D) Growth curves of control, DMP1-GsaKO, and genetic background matched DMP1-Cre only mice (n ! 10). (E) Nose to anus body length from 12-week-old and 21-week-old control (Con) (n ¼ 6) and DMP1-GsaKO (KO) mice (n ¼ 6). DXA analysis showing normalized whole-body (F) fat and (G) lean mass in 21-week-old control (Con) (n ¼ 10) and DMP1-GsaKO (KO) (n ¼ 7). (H) Serum leptin levels from 21-week-old control (Con) (n ¼ 13) and DMP1-GsaKO (KO) mice (n ¼ 10). (I) Representative images of GWAT (top panel) and InWAT (bottom panel) from control (Con), and DMP1-GsaKO (KO) mice. (J) Individual GWAT, InWAT, BAT, and pancreas organ weights normalized to total body weights from 21-week-old control (Con) (n ¼ 7) and DMP1-GsaKO (KO) mice (n ¼ 7). All data: mean AE SE, Ã p < 0.05.
and Gsa mRNA-protein expressions were normal in other metabolic tissues including gonadal WAT (GWAT), inguinal WAT (InWAT), BAT, pancreas, and liver ( Fig. 1A-C) . It should be noted that mice lacking Gsa in skeletal muscle do not have a body composition phenotype. (41) DMP1-GsaKO had significantly decreased body weight compared to control littermates beginning at 5 weeks of age (Fig. 1D) . Mice carrying the Cre-only transgene (DMP1-Cre) on the same genetic background of the DMP1-GsaKO mice were indistinguishable from controls (Gsa flox/flox )( F i g .1 D). Therefore, littermates lacking Cre expression DMP1-Cre (-) : Gsa (flox/flox) were used as controls for all subsequent experiments. The body lengths of DMP1-GsaKO mice were similar at 12 weeks of age and were significantly decreased only at 21 weeks of age (Fig. 1E ). DXA showed a significant decrease in absolute (Supporting Fig. 1A ) and normalized ( Fig. 1F ) whole-body fat mass in DMP1-GsaKO mice. Lean mass was significantly decreased in DMP1-GsaKO mice (Supporting Fig. 1B ), but was significantly increased after correcting for the decreased body weight (Fig. 1G) . Serum leptin, which correlates with body adiposity, (42, 43) was also significantly decreased in the DMP1-GsaKO mice (Fig. 1H ). Necropsy showed marked reduction in WAT depots including GWAT and InWAT depots (Fig. 1I, J) . The organ weights of other metabolic organs including BAT, pancreas ( Fig. 1J) , liver, and skeletal muscles (data not shown) were not changed. Similar to the female DMP1-GsaKO mice ( Fig. 1 ), male DMP1-GsaKO mice also had significant decrease in body weight, GWAT, and InWAT (Supporting Fig. 1C, D) . These data show that loss of Gsa-signaling in osteolineage cells decreases body adiposity.
Mice lacking Gsa in mature osteoblasts and osteocytes have decreased WAT mass Next we sought to validate the body fat changes in DMP1-GsaKO mice using another similar mouse model of OC-GsaKO ( Fig. 2A) . Littermates lacking Cre expression OC-Cre (-) :Gsa (flox/ flox) were used as controls for all experiments because presence of OC-Cre transgene does not alter body composition. (44) CreloxP recombination (Fig. 2B ) and decreased Gsa mRNA expression (Fig. 2C) were observed only in skeletal tissues and not in other metabolic tissues of OC-GsaKO mice (Fig. 2B, C) . The mice had significantly reduced body weight starting at 9 weeks of age (Fig. 2D ). These mice were shorter from early age and had significantly reduced body length by 12 weeks of age (Fig. 2E) . DXA analysis showed that these mice were osteopenic (Fig. 2F) , and had significantly reduced absolute whole-body fat and lean mass (Supporting Fig. 2A, B) . After normalizing for the decreased body weight, OC-GsaKO mice continued to have significant reduction in body fat (Fig. 2G ), but had significantly increased lean mass (Fig. 2H) . Serum leptin was significantly decreased in OC-GsaKO mice (Fig. 2I) . Gross appearances showed markedly reduced sizes of GWAT and InWAT (Fig. 2J) . Normalization of absolute weights of GWATs and InWATs to respective body weights were significantly decreased in the OC-GsaKO mice compared to control littermates, whereas absolute or normalized weights of BAT and pancreas were not altered (Fig. 2K) . Similar to females, male OC-GsaKO mice also had significant decrease in body weight (Supporting Fig. 2C ), reduced absolute and normalized body fat (Supporting Fig. 2D ), osteopenia (Supporting Fig. 2E ), and significantly reduced GWAT organ weight (Supporting Fig. 2F , G).
Mice with postnatal loss of Gsa in osteocytes have reduced WAT mass Next we examined body composition of mice with inducible loss of Gsa in osteocytes (DMP1-ERT2-GsaKO) by treating these mice with tamoxifen from 10 weeks of age until 18 weeks of age. The DMP1-Cre-ERT2 mice expression has been shown to be specific to osteocytes and a few mature osteoblasts. (36) Before beginning of tamoxifen treatment, body weight (Supporting Fig. 3A) , BMD (Supporting Fig. 3B ), bone mineral content (Supporting Fig. 3C ), body lean mass (Supporting Fig. 3D ), and fat mass (Supporting Fig. 3E) were similar between the DMP1-ERT2-GsaKO and control littermates. At the end of the 8-week tamoxifen treatment, total body weights were not significantly changed (Fig. 3A) . As expected, these mice developed osteopenia (Fig. 3  B) , indicating an essential role of Gsa signaling postnatally in regulating bone mass. (45) DXA analysis showed a significant decrease in absolute (Supporting Fig. 3F ) and normalized (Fig. 3C) whole-body fat mass in DMP1-ERT2-GsaKO mice. The absolute (Supporting Fig. 3G) or corrected (Fig. 3D ) lean mass were not altered in tamoxifen-treated DMP1-ERT2-GsaKO mice. Femur lengths at the end of the tamoxifen treatment were not different from littermate controls (Fig. 3E) , indicating that the changes in whole-body fat in these mice are independent of changes in body size. In accordance with the DXA analysis, GWAT and InWAT gross appearances were markedly decreased and organ weights normalized for total body weight were significantly reduced in DMP1-ERT2-GsaKO mice (Fig. 3F, G) . The normalized organ weights of other metabolic organs including pancreas (Fig. 3H) and BAT (Fig. 3I) were not changed. Taken together, the three constitutive and inducible mouse models of Gsa deletion in osteolineage cells indicate that osteolineage cells contribute to body fat accumulation.
The lean phenotype of mice lacking Gsa in osteocytes is associated with increase in energy expenditure
The decreased body adiposity in the mice lacking Gsa in osteolineage cells could be due to altered energy balance. Combined food intake, physical activity, or oxygen consumption over a 24-hour period were not changed in DMP1-GsaKO mice (Supporting Fig. 4A-C) . Close examination showed that although food intake (Supporting Fig. 4A ) and physical activity (Supporting Fig. 4C ) were significantly reduced during the 12-hour dark cycle, oxygen consumption was normal during the dark cycle in DMP1-GsaKO mice and there was a tendency to increased oxygen consumption during the light cycle (p ¼ 0.064) (Supporting Fig. 4C ). Therefore, DMP1-GsaKO mice have a sustained increase in energy expenditure that, at least in part, drives the decrease in body fat.
Mice lacking ucOCN are obese, which is associated with decreased insulin secretion and pancreatic b-cell proliferation. (1) Therefore, the lean phenotype of mice lacking Gsa in osteolineage cells could be due to increased ucOCN and insulin secretion. However, serum insulin levels were normal in DMP1-GsaKO, OC-GsaKO, and DMP1-ERT2-GsaKO (Supporting Fig. 4D-F) . Pancreatic b-cell area, as determined by insulin immunohistochemistry, was not changed in DMP1-GsaKO mice (Supporting Fig. 4G, H) . Further examination of glucose metabolism and insulin action by hyperinsulinemic-euglycemic clamps showed normal levels of glucose infusion rate (GIR), basal and clamp hepatic glucose production, glucose turnover, glycolysis, and glycogen synthesis in DMP1-GsaKO mice (Supporting Fig. 4I ). Serum osteocalcin (OC) levels were significantly decreased in DMP1-GsaKO (Supporting Fig. 4J ) and OC-GsaKO (Supporting Fig. 4L ) mice. Serum ucOCN showed decreasing trend in DMP1-GsaKO mice (Supporting Fig. 4K ) and was significantly decreased in OC-GsaKO mice (Supporting Fig. 4M ). Taken together, these data show that the reduction in WAT in mice lacking Gsa in osteolineage cells is independent from ucOCN.
Beige adipogenesis is increased in mice lacking Gsa in osteolineage cells
Histological examination of WAT from DMP1-GsaKO, OC-GsaKO, and DMP1-ERT2-GsaKO mice (Fig. 4 A-C) showed markedly smaller adipocytes with significantly reduced adipocyte surface area (Supporting Fig. 5A ). These smaller adipocytes appeared as clusters of brown-adipocyte-like multilocular adipocytes or beige adipocytes. Immunohistochemical staining for beige adipogenic marker UCP1 showed marked increase in UCP1-positive cells in GWATs from DMP1-GsaKO, OC-GsaKO, and DMP1-ERT2-GsaKO (Fig. 4D-F) . Lower magnification imaging showed that the UCP1þ adipocytes are more widespread throughout the WATs (Supporting Fig. 5B) . Similarly, InWATs from DMP1-GsaKO mice (Supporting Fig. 5C ) and OC-GsaKO (Supporting Fig. 5D ) also showed a widespread increase in UCP1þ beige adipocytes. Beige adipogenic gene markers including UCP1, Cox5b, Dio2, Cidea, and/or Elovl3 were . (E) Nose to tail-base body length from 12-week-old control (Con) (n ¼ 6) and OC-GsaKO (KO) mice (n ¼ 5). Noninvasive DXA showing (F) BMD, (G) normalized whole-body fat, and (H) normalized lean mass in 12-week-old control (Con) (n ¼ 9) and OC-GsaKO (KO) mice (n ¼ 7). (I) Serum leptin levels from 21-week-old control (Con) (n ¼ 9) and OC-GsaKO (KO) mice (n ¼ 8). (J) Representative gross images showing sizes of GWAT and InWAT from 15-week-old control and OC-GsaKO mice. (K) Individual GWAT, InWAT, BAT, and pancreas organ weights normalized to total body weights from 21-week-old control (Con) (n ¼ 8) and OC-GsaKO (KO) mice (n ¼ 6). All data: mean AE SE; Ã p < 0.05.
significantly increased in InWATs of DMP1-GsaKO, OC-GsaKO, and DMP1-ERT2-GsaKO ( Fig. 4G-I ). We next examined the expressions of white adipogenic genes. Gene expression of master regulator of adipocyte differentiation PPARg but not the co-regulator of differentiation CEBPa and SREBP1, were significantly reduced in InWATs from both DMP1-GsaKO (Fig. 4J ) and OC-GsaKO (Fig. 4K) . This was accompanied with significant decrease in perilipin (PLIN), PPARa, and Acox1 (Fig. 4J,  K) . Interestingly, these parameters of white adipocyte differentiation were not significantly changed in InWATs from DMP1-ERT2-GsaKO mice (Fig. 4L) , suggesting that the increased beige adipogenesis most likely precedes the decrease in white adipogenesis in the DMP1-GsaKO and OC-GsaKO mice. We next focused on mechanisms through which Gsa-deficient osteocytes could increase beige adipogenesis.
Osteocyte-secreted Wnt signaling inhibitor sclerostin contributes to the increased beige adipogenesis
White and beige adipogenic differentiation of the stromal vascular fraction (SVF) cells from InWATs of control and DMP1-GsaKO mice were similar (Supporting Fig. 6A, B) . Therefore, the increased beige adipogenesis in these mice is not intrinsic to the adipose tissue but imposed by external factors. Recently skeletal muscle-secreted factors meteorin-like (46) and irisin (47) have been shown to increase beige adipogenesis, raising the possibility that factors secreted from bone cells could alter the secretion of these factors from skeletal muscle. Whereas the serum levels of myokine meteorin-like were not changed (Supporting Fig. 6C ), serum irisin levels were significantly increased in DMP1-GsaKO, OC-GsaKO, and DMP1-ERT2-GsaKO mice (Supporting Fig. 6D , E). As described in the Introduction, activated Wnt-signaling is an inhibitor of UCP1-expression in differentiated brown adipocytes and mice with heterozygous loss of sclerostin receptor LRP6 show significantly increased UCP1 expression in both brown and beige depots. (19) Interestingly, sclerostin-deficient mice had significantly increased body fat mass, (48) suggesting that sclerostin may play a role in beige adipogenesis. Serum sclerostin levels were significantly increased in the DMP1-GsaKO, OC-GsaKO, and DMP1-ERT2-GsaKO mice (Fig. 5A) . Sclerostin expression in cortical bones of OC-GsaKO (Fig. 5B) and DMP1-ERT2-GsaKO mice (Fig. 5C) were also increased similar to previous findings in DMP1-GsaKO animals. (32) Examination of Wnt signaling in WAT showed significant reduction in expression of Axin2, a canonical Wnt signaling target gene, in DMP1-GsaKO mice (Fig. 5D) . At the protein level, total b-catenin (Fig. 5E, F) and nonphosphorylated active b-catenin (Fig. 5G, H) immunostainings were strikingly reduced in the beige adipocytes in DMP1-GsaKO, OC-GsaKO, and DMP1-ERT2-GsaKO mice relative to the control cells and endothelial cells lining blood Fig. 3 . Inducible loss of Gsa in osteocytes in adult mice also leads to decreased WAT. (A) Total body weight, (B) whole-body BMD, (C) normalized wholebody fat, (D) normalized whole-body lean mass, and (E) femur length in 18-week-old control (Con) (n ¼ 6) and DMP1-ERT2-GsaKO (KO) (n ¼ 7) treated with tamoxifen from 10 to 18 weeks of age. Individual organ weights of (F) GWAT, (G) InWAT, (H) pancreas, and (I) BAT normalized to total body weights from 18-week-old control (Con) (n ¼ 6) and DMP1-ERT2-GsaKO (KO) (n ¼ 6) mice treated with tamoxifen from 10 to 18 weeks of age. All data: mean AE SE, Ã p < 0.05. Fig. 4 . Beige adipogenesis is increased in mice lacking Gsa in osteolineage cells. Representative H&E staining of GWATs from (A) DMP1-GsaKO, (B) OCGsaKO, and (C) DMP1-ERT2-GsaKO mice with corresponding control littermates (n ¼ 4). UCP1 IHC staining from (D) DMP1-GsaKO, (E) OC-GsaKO, and (F) DMP1-ERT2-GsaKO mice (n ¼ 3). Gene expressions of beige adipogenesis markers PRDM16, Cox5b, Dio2, Cidea, Elovl3, and UCP1 in InWAT from (G) DMP1-GsaKO, (H) OC-GsaKO, and (I) DMP1-ERT2-GsaKO mice with corresponding control littermates (n ¼ 5). Expressions of white adipogenesis markers PPARg, CEBPa, SREBP1, PPARa, PLIN, Acox1, and Acls1 in InWAT of (J) DMP1-GsaKO, (K) OC-GsaKO, and (L) DMP1-ERT2-GsaKO mice with corresponding control littermates (n ¼ 5). All data: mean AE SE; Ã p < 0.05. vessels (Supporting Fig. 6F ). Immunostaining for nonphosphorylated active b-catenin was present in nucleus and cytoplasm of adipocytes from control mice (Fig. 5F ). By contrast, the active b-catenin staining was markedly absent from most of the beige adipocytes from the KO mice (Fig. 5G) . The cooccurrence of decreased canonical Wnt signaling in beige adipocytes coupled with increased circulating serum sclerostin suggested a role of sclerostin in regulating beige adipogenesis.
Next we examined whether sclerostin could directly induce expressions of beige adipogenic genes. SVF undergoing brown adipogenic differentiation were treated with sclerostin (0.2 to 20 ng/mL) after their initial differentiation commitment for 5 days in lower incubator temperature of 33°C. Sclerostin dosedependently increased expression of UCP1 and PGC1a in primary adipocytes (Fig. 6A) . Sclerostin treatment (200 ng/mL) of beige adipogenic SVF significantly rescued the reduction of PGC1a and UCP1 induced by Wnt-3a treatment (Fig. 6B) . To examine the in vivo effects of Sclerostin, wild-type mice were administered 100 mg/kg of sclerostin every day for 3 weeks. Although sclerostin treatment did not alter total body weight (Supporting Fig. 7E ), it significantly reduced normalized tissue weights of WAT (Fig. 6C) . The weights of other tissues including BAT and pancreas were not changed (Supporting Fig. 7E ). Quantitative PCR showed that the continuous sclerostin treatment significantly increased UCP1 expression (Fig. 6D) .
We have previously shown that Gsa-deficient osteocytic cells have significant increase in expression of SOST/sclerostin. (31) Here, we engineered an osteocytic cell line Ocy454 lacking Gsa using the CRISPR-Cas9 technique (Supporting Fig. 7A ). The GsaKO Ocy454 cells had a time-dependent increase in sclerostin expression over control cells (Supporting Fig. 7B ). Sclerostin was also significantly increased in conditioned media (CM) of GsaKO Ocy454 cells (Fig. 6E) . Using a sclerostin antibody we could deplete sclerostin from the CM of GsaKO Ocy454 cells by 10-fold (Fig. 6E) . Primary adipocytes from wild-type mice undergoing beige adipogenic differentiation were treated with 20% (vol/vol) CM from GsaKO Ocy454 cells. Treatment with 20% (vol/vol) CM from Ocy454 cells significantly increased expression of UCP1 and PGC1a in primary adipocytes undergoing beige adipogenic differentiation compared to no treatment control group (Fig. 6F) . CM from GsaKO Ocy45 cells significantly increased UCP1 and Elovl3 expression compared to the control group (Fig. 6F) . Sclerostin depletion significantly reduced expression of UCP1 and Elovl3 induced by Gsa-KO Ocy454 cells CM (Fig. 6F) . CM from Gsa-KO Ocy454 cells modestly but significantly increased expression of PPARg in primary adipocytes undergoing white adipogenic differentiation (Supporting Fig. 7D ), but UCP1 expression was undetectable in these cells. This data suggests that the increased beige adipogenesis in mice lacking Gsa in osteolineage cells is in part mediated by sclerostin effects on WAT. Finally, we treated DMP1-GsaKO mice with antisclerostin neutralizing antibody for 2 weeks to investigate whether normalizing sclerostin level in these animals could rescue the adipose tissue phenotype. Anti-sclerostin antibody significantly decreased serum sclerostin levels in DMP1-GsaKO mice (Fig. 6G) and did not alter serum insulin or serum irisin levels in these animals (Supporting Fig. 7C) . In InWAT tissues, this treatment significantly reduced the expression of UCP1 and PGC1a in the DMP1-GsaKO mice compared to the IgG-antibody treatment (Fig. 6H) , showing that the increased beige adipogenesis in these mice is partly mediated by direct effect of Sclerostin on WAT.
Discussion
Here we report that the osteocyte-secreted factor sclerostin contributes to increased beige adipogenesis in vivo and in vitro. Presence of increased beige adipogenesis in the three genetic mouse models DMP1-GsaKO, OC-GsaKO, and DMP1-ERT2-GsaKO with high circulating sclerostin supports this notion. Although DMP1-Cre expressed in a small population of skeletal muscle cells, in addition to osteocytes, the body composition phenotypes of DMP1-GsaKO mice are not due to loss of Gsa signaling in muscle because mice with Gsa disruption in skeletal muscle have a normal body composition. (41) The OC-GsaKO and DMP1-ERT2-GsaKO, in which OC-Cre or DMP1-ERT2-Cre are expressed only in skeletal tissues, also display similar lean and beige adipogenic phenotypes, showing that the phenotypes are driven by Gsa ablation in osteogenic cells. Mice with WAT, b-cell, or liver-specific homozygous Gsa deletion are also lean (49) ; however, there was no Cre-loxP recombination observed in these tissues from either of the OC-GsaKO, DMP1-GsaKO, or DMP1-ERT2-GsaKO mice. Taken together, these data indicate that the lean phenotypes of mice lacking Gsa in osteolineage cells are direct effect of Gsa deficiency in mature osteoblasts and osteocytes.
Altered body size between comparison groups adds complexity in evaluating the metabolic or body composition phenotypes, especially with altered skeletal phenotype. Smaller-sized mice are expected to face higher thermoregulatory demands due to their increased heat loss from a relatively greater surface area. Smaller mice have been shown to cope with this by decreasing their core body temperature or possibly by increasing the insulation quality of their fur. (50) In most dwarf mice this thermoregulatory adjustment leads to positive energy balance and obesity. Although OC-GsaKO mice were also shorter by 5 weeks of age, body lengths of DMP1-GsaKO mice were not different compared to controls by 12 weeks of age. DMP1-GsaKO mice show a significantly reduced body weight by 5 weeks of age, indicating that the lean phenotype precedes the reduced body length. Furthermore, conditional ablation of Gsa in adult DMP1-ERT2-GsaKO mice upon tamoxifen injections from 10 to 18 weeks of age resulted in a lean phenotype although the body length remained unaltered. These data clearly indicate that the lean phenotypes due to Gsa deficiency in osteolineage cells are independent of body size.
Our previous analysis has shown increased circulating myeloid cells in DMP1-GsaKO mice (32) and cytokines secreted from hematopoietic lineage cells have been shown to increase beige adipogenesis and thermogenesis. (46, 51) It is possible that increased circulating myeloid cells or cytokines in DMP1-GsaKO mice can contribute to the increased beige adipogenesis. However, mice with postnatal deletion of Gsa in osteocytes-DMP1-ERT2-GsaKO mice-do not show changes in hematopoietic lineages (data not shown) but still have increased beige adipogenesis, indicating that factors independent of immune cells are contributing to the beige adipogenesis. Moreover, our in vitro CM experiments show that factors secreted from osteocytes, and specifically sclerostin, can induce UCP1 and other beige adipogenic markers in SVF. Similarly, increased sympathetic tone is a well-known contributor to increased beige adipogenesis. Although we cannot exclude a relative contribution of both the sympathetic tone or circulating cytokines in our in vivo model, our in vitro experiments showed that osteocytes indeed directly regulate adipogenesis through secreted factors.
As a negative regulator of Wnt signaling, high sclerostin levels are expected to correlate with lower BMD and increased risk of fractures. However, multiple studies show that sclerostin levels do not necessarily follow an expected pattern with BMD, bone turnover markers, and fracture risk. (52) Potential sources of biological variability, clearance rate from circulation, and even assay standardization may confound these findings.
(52) Nonetheless, sclerostin neutralizing antibody is a potent anabolic treatment for postmenopausal osteoporosis, (26) highlighting the clinical utility of sclerostin for disease prevention. Our findings suggest that sclerostin may contribute negatively to obesity by increasing beige adipogenesis without affecting glucose metabolism. Serum sclerostin is increased in non-obese diabetic patients (53) and during aging, (54) conditions characterized by decreased metabolism and tendency to increased body fat. However, similar to bone fractures, correlation of sclerostin and body fat is confounding due to the presence of other biologically variable factors. In postmenopausal older Japanese women, serum sclerostin levels were positively correlated with abdominal and gonadal fat. (55) However, sclerostin levels did not change in obese young adult patients with metabolic syndrome, or after weight loss inducing bariatric surgery. (56, 57) Moreover, assessment of beige adipocytes in normal adults or patients has not been widely examined at this time. (58) Therefore, changes in beige adipogenesis in physiological conditions with high circulating sclerostin levels or after anti-sclerostin antibody treatment remain to be examined. Previous studies have shown that circulating irisin and sclerostin were highly correlated in human adults. (59) However, reducing circulating sclerostin to normal levels in DMP1-GsaKO mice using sclerostin-neutralizing antibody did not change circulating irisin levels in these mice and yet had reduced expression of beige adipogenic markers. This indicates that the increased beige adipogenesis effect in these studies is primarily from increased sclerostin levels. Further studies are needed to understand the contribution of the Wnt signaling inhibitor sclerostin on white, brown, or beige fat development.
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